Allena Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Allena Pharmaceuticals has raised $28.0M across 1 funding round on record, the most recent a Post-IPO Equity of $28.0M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Allena Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Jul 2021.
Allena Pharmaceuticals Funding Rounds
Allena Pharmaceuticals Founders and Leadership Team
Contact details for the Allena Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Allena Pharmaceuticals Funding Compared to Other Biotechnology Startups
Allena Pharmaceuticals' latest round of $28.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Allena Pharmaceuticals in Biotechnology and Newton
Companies Similar to Allena Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Allena Pharmaceuticals Funding FAQs
What does Allena Pharmaceuticals do?
Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
How much funding has Allena Pharmaceuticals raised?
Allena Pharmaceuticals has raised $28.0M across 1 round on record. The most recent is a Post-IPO Equity of $28.0M announced in Jul 2021.
When did Allena Pharmaceuticals last raise funding?
Allena Pharmaceuticals' most recent funding round on record is a Post-IPO Equity of $28.0M, announced in Jul 2021.
Who is the CEO of Allena Pharmaceuticals?
Lou Brenner is listed as CEO at Allena Pharmaceuticals.
Where is Allena Pharmaceuticals headquartered?
Allena Pharmaceuticals is based in Newton, Massachusetts, United States.
How many employees does Allena Pharmaceuticals have?
Allena Pharmaceuticals is in the 51-100 employee band.
How does Allena Pharmaceuticals' funding compare to other Biotechnology startups?
Allena Pharmaceuticals' latest round of $28.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Allena Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Allena Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.